James A. Heslop

FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2

Teresa Brevini, Mailis Maes, Gwilym J. Webb et al. · Nature · 2022 · 282 citations · Full text

Mechanistic evaluation of primary human hepatocyte culture using global proteomic analysis reveals a selective dedifferentiation profile

James A. Heslop, Cliff Rowe, Joanne Walsh et al. · Archives of Toxicology · 2016 · 135 citations · Full text

Drug Disposition, Key Factors, Selective Dedifferentiation Profile +22

GATA6 defines endoderm fate by controlling chromatin accessibility during differentiation of human-induced pluripotent stem cells

James A. Heslop, Behshad Pournasr, Jui-Tung Liu et al. · Cell Reports · 2021 · 69 citations · Full text

Genetics, Chromatin Accessibility, Epigenetics +20

MicroRNA-122: A Novel Hepatocyte-Enriched in vitro Marker of Drug-Induced Cellular Toxicity

Richard Kia, Lorna Kelly, Rowena Sison‐Young et al. · Toxicological Sciences · 2014 · 38 citations · Full text

Cell Culture Media, Immunology, Cell Death +21

Implications of Applying a Private Sector Based Reporting Model to Not‐for‐Profit Entities: The Treatment of Charitable Distributions by Charities in New Zealand

Chris van Staden, James A. Heslop · Australian Accounting Review · 2009 · 21 citations

Corporate Tax, Law, Public-private Partnership +19